News

News Archive

European Commission Approves Menarini Group’s ORSERDU<sup>®</sup> (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

FLORENCE (Italy) and NEW YORK, NY, September 20, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More